DNTH

Dianthus Therapeutics, Inc. /DE/

Tremor tracks 2 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

DNTHDianthus Therapeutics
10Calm
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
Running, no new patientsPhase 265 patientsMain results: Jul 28, 2025
DNTHDianthus Therapeutics
0Calm
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Signing up patientsPhase 3195 patientsMain results: Dec 2028

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

38 sales (0 not pre-planned) · 0 purchases

CARR EDWARDCHIEF ACCOUNTING OFFICER · Sep 17, 2026Sold 7,928 sharesabout $796 thousand · pre-planned
CARR EDWARDCHIEF ACCOUNTING OFFICER · Sep 17, 2026Sold 6,771 sharesabout $686 thousand · pre-planned
CARR EDWARDCHIEF ACCOUNTING OFFICER · Sep 17, 2026Sold 3,501 sharesabout $358 thousand · pre-planned
CARR EDWARDCHIEF ACCOUNTING OFFICER · Sep 17, 2026Sold 1,100 sharesabout $114 thousand · pre-planned
CARR EDWARDCHIEF ACCOUNTING OFFICER · Sep 17, 2026Sold 700 sharesabout $73 thousand · pre-planned
Randhawa SimratEVP, Head of R&D · Sep 1, 2026

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.